Next Round of GWAS a 'Wait-and-See Situation,' Says Illumina CEO
June 14, 2011
Next Round of GWAS a 'Wait-and-See Situation,' Says Illumina CEO
Though Illumina has been predicting a second round of association studies run on chips containing rare variant content, CEO Jay Flatley said that the market is "at the very beginning" of this new phase, which Illumina refers to as "rich GWAS."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Illumina's Q2 Sales Rise 36 Percent on Sequencing Demand, 'Overall Improvement' in Array Sales
August 2, 2011 / BioArray News - Illumina CEO 'Optimistic' about Array Business as Q1 Sales Spike 47 Percent
May 3, 2011 / BioArray News - Illumina CEO: Array Market Returned to 'Normalcy' in 2010 as BeadChip Sales Rose 10 Percent
January 18, 2011 / BioArray News - Illumina CFO Predicts GWAS Market Will Return to 'Normal State' in 2010
September 22, 2009 / BioArray News - Q&A: Chinese GWAS Expert Yongyong Shi Makes the Case for Population-Specific Arrays
December 18, 2012 / BioArray News